Year: 2013

Bionor Pharma’s “Kick, Kill & Boost” Strategy Advances – Romidepsin Chosen as the “Kick”

Oslo 10.09.2013 – Bionor Pharma ASA (OSE: BIONOR) announces that the Company has chosen romidepsin for the planned combination study with Vacc-4x, after considering various HDAC inhibitors (HDACi). Romidepsin is marketed in the US as Istodax® by Celgene Corporation Inc. The “Kick, Kill” study is planned to be conducted by the HIV research team at …

Read more

Analysis of Immune Responses in Patients Treated with Vacc-4x Supports Further Development

Boston 12.09.2012 – Researchers from the Vaccine Immunotherapy Center at the Lausanne University Hospital presented yesterday immunological data from the phase II study with Vacc-4x during an oral session at the AIDS Vaccine 2012 conference in Boston. News Summary • Data from Vacc-4x study presented at the largest and most prestigious global scientific conference focused …

Read more